Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

• Published in: Mediators of inflammation 2020, Vol.2020 (2020), p.1-13
• Main Authors: Fendler, Wojciech, Szemraj, Janusz, Robak, Tadeusz, Misiewicz, Małgorzata, Wawrzyniak, Ewa, Ferlińska, Magdalena, Jarych, Dariusz, Mikulski, Damian, Dróżdż, Izabela, Węgłowska, Edyta, Robak, Paweł, Smolewski, Piotr
• Format: Article
• Language: English
• Subjects: B cells; Bone marrow; Bortezomib; Calcium; Care and treatment; Carfilzomib; Chemokines; Cytokines; Development and progression; Fibroblasts; Granulocytes; Hemoglobin; Hypercalcemia; Interleukin 1 receptor antagonist; Interleukin 1 receptors; Interleukin 8; Interleukin 9; Laboratories; Monocyte chemoattractant protein 1; Multiple myeloma; Patients; Proteins; Renal insufficiency; Targeted cancer therapy; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Vascular endothelial growth factor
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2020/1835836

The aim of the study was to determine the levels of selected cytokines and chemokines in the serum of multiple myeloma (MM) patients treated with bortezomib-based regimens. A total of 71 MM patients were examined: 41 with primary refractory disease (17) or early relapse (28), and 30 who were bortezomib sensitive with no progression for at least six months. Patients who demonstrated CR or PR after bortezomib-based therapies longer than six months after treatment discontinuation were designated bortezomib sensitive. Serum cytokine levels were assayed with Bio-Rad Bio-Plex Pro Human Cytokine 27-Plex Assay on the MAGPIX Multiplex Reader and the Bio-Plex® 200 System (Bio-Rad). Higher levels of MIP-1α and lower levels of MIP-1β and IL-9 were associated with better responses to bortezomib-based treatment, and higher levels of IL-1ra and IL-8 were associated with bone involvement. MCP-1 was elevated in patients with hemoglobin